Cardiff Oncology, Inc. (CRDF) - 10-K Summary
Business Context and Reporting Period
Company: Cardiff Oncology, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Overview: Cardiff is a clinical-stage biotechnology company developing onvansertib, an oral, highly selective Polo-like Kinase 1 (PLK1) inhibitor. The company focuses on combination therapies for RAS-mutated metastatic colorectal cancer (mCRC) and other indications including metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple-negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML).
Recent Leadership Change: On January 27, 2026, Mani Mohindru was appointed Interim CEO following the departure of CEO Mark Erlander and CFO James Levine.
Key Financial Metrics (Year Ended Dec 31, 2025)
| Metric | 2025 | 2024 |
|---|---|---|
| Revenue | $0.6 million | $0.7 million |
| Net Loss | $(45.9) million | $(45.4) million |
| Net Loss Attributable to Common Stockholders | $(45.9) million | $(45.5) million |
| Operating Expenses | $49.6 million | $49.3 million |
| Research & Development (R&D) | $35.3 million | $36.9 million |
| Selling, General & Administrative (SG&A) | $14.2 million | $12.5 million |
| Cash, Cash Equivalents & Short-Term Investments | $58.3 million | $91.7 million |
| Working Capital | $43.7 million | $81.6 million |
| Accumulated Deficit | $(430.0) million | $(384.2) million |
Note: Revenue is derived from legacy intellectual property licenses unrelated to onvansertib. The company has no product sales.
Material Changes vs. Prior Period
- Liquidity Decline: Cash and short-term investments decreased by approximately $33.4 million year-over-year, driven by a net cash burn of $37.9 million in operating activities.
- Expense Management: R&D expenses decreased by $1.5 million primarily due to reduced clinical trial and preclinical activity costs. Conversely, SG&A expenses increased by $1.7 million, driven by higher professional fees (strategic advisory services) and patent fees, as well as employee severance costs.
- Stock-Based Compensation: Total stock-based compensation increased to $5.7 million in 2025 from $4.8 million in 2024.
- Capital Structure: The company raised $2.6 million in financing activities in 2025 (warrant and option exercises) compared to $53.8 million in 2024 (equity sales).
Guidance, Outlook, Risks, and Contingencies
Going Concern Uncertainty
Management and the independent auditor have expressed substantial doubt about the company's ability to continue as a going concern. Current capital resources ($58.3 million) are projected to fund operations only into the first quarter of 2027. The company requires additional equity or debt financing to continue development and commercialization efforts.
Clinical Development Outlook
- CRDF-004 (mCRC): Updated data (Jan 2026) from the Phase 2 trial showed the 30mg dose of onvansertib + FOLFIRI/bev achieved a 72.2% Objective Response Rate (ORR) vs. 43.2% for Standard of Care (SoC). Progression-Free Survival (PFS) Hazard Ratio was 0.37 vs. SoC. The company plans to initiate a Phase 3 trial (CRDF-005) contingent on these results.
- Other Programs: Investigator-initiated trials are ongoing in mPDAC, SCLC, mTNBC, and CMML with preliminary data showing promise in mTNBC (40% ORR) and CMML (approx. 40% efficacy).
Material Risks and Contingencies
- Intellectual Property Dispute: On February 18, 2026, Nerviano Medical Sciences (licensor of onvansertib) sent a notice alleging material breach of the license agreement regarding joint ownership of certain patents and a joint invention continuation application. Nerviano may terminate the agreement if the breach is not cured, which would result in the loss of rights to onvansertib.
- Regulatory Risk: As a clinical-stage company, the business is entirely dependent on the successful completion of clinical trials and regulatory approval, which is uncertain.
- Stock Volatility: Common stock price ranged from $1.95 to $4.78 during 2025.
Investor Verification Checklist
- Capital Runway: Verify the timeline for the next financing round given the "substantial doubt" going concern opinion and cash burn rate of ~$38M/year.
- License Dispute Status: Monitor the resolution of the February 2026 notice from Nerviano Medical Sciences regarding patent ownership and potential license termination.
- CRDF-004 Trial Design: Confirm the finalized design and FDA agreement for the proposed Phase 3 trial (CRDF-005) based on the interim Phase 2 data.
- Leadership Stability: Assess the impact of the recent executive departures (CEO/CFO) and the appointment of an Interim CEO on strategic execution.
- Patent Portfolio: Review the specific claims of the disputed patents (Nos. 12,144,813 and 12,263,173) and their criticality to the mCRC indication.